MX9206762A - Derivados de indol - Google Patents

Derivados de indol

Info

Publication number
MX9206762A
MX9206762A MX9206762A MX9206762A MX9206762A MX 9206762 A MX9206762 A MX 9206762A MX 9206762 A MX9206762 A MX 9206762A MX 9206762 A MX9206762 A MX 9206762A MX 9206762 A MX9206762 A MX 9206762A
Authority
MX
Mexico
Prior art keywords
pct
image
date
sec
compounds
Prior art date
Application number
MX9206762A
Other languages
English (en)
Inventor
John E Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9206762A publication Critical patent/MX9206762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX9206762A 1991-11-25 1992-11-24 Derivados de indol MX9206762A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79674491A 1991-11-25 1991-11-25

Publications (1)

Publication Number Publication Date
MX9206762A true MX9206762A (es) 1993-05-01

Family

ID=25168947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9206762A MX9206762A (es) 1991-11-25 1992-11-24 Derivados de indol

Country Status (30)

Country Link
US (1) US5639752A (es)
EP (1) EP0619805B1 (es)
JP (2) JP2840448B2 (es)
KR (1) KR0184911B1 (es)
CN (1) CN1045294C (es)
AT (1) ATE190608T1 (es)
AU (1) AU671959B2 (es)
BR (1) BR9206810A (es)
CA (1) CA2124206C (es)
CZ (1) CZ281874B6 (es)
DE (1) DE69230803T2 (es)
DK (1) DK0619805T3 (es)
EG (1) EG21209A (es)
ES (1) ES2143992T3 (es)
FI (1) FI942395A0 (es)
GR (1) GR3033370T3 (es)
HU (1) HUT69705A (es)
IL (1) IL103798A (es)
MX (1) MX9206762A (es)
MY (1) MY109954A (es)
NO (1) NO301225B1 (es)
NZ (2) NZ245243A (es)
PL (1) PL173875B1 (es)
PT (1) PT101087B (es)
RU (1) RU2126399C1 (es)
TW (1) TW229205B (es)
UA (1) UA41297C2 (es)
WO (1) WO1993011106A1 (es)
YU (1) YU48456B (es)
ZA (1) ZA929082B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
KR0184911B1 (ko) * 1991-11-25 1999-05-01 알렌 제이. 스피겔 인돌유도체
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
JP2644088B2 (ja) 1992-04-07 1997-08-25 フアイザー・インコーポレイテツド ５−ｈｔ１作動薬としてのインドール誘導体
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
NZ251047A (en) * 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
AU672802B2 (en) * 1992-07-24 1996-10-17 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5965582A (en) * 1994-08-03 1999-10-12 Asta Medica Aktiengesellschaft N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunemodulating effect
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
TR199700993T1 (xx) * 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
WO1997018212A1 (en) * 1995-11-14 1997-05-22 Pharmacia & Upjohn S.P.A. Aryl and heteroaryl purine compounds
ATE209666T1 (de) * 1996-02-23 2001-12-15 Dow Chemical Co Dispersionen aus schichtgespaltenen partikeln in kunststoffschäumen
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
EP1003738B1 (en) * 1997-08-09 2003-11-19 SmithKline Beecham plc Bicyclic compounds as ligands for 5-ht1 receptors
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
ATE271555T1 (de) 1998-01-14 2004-08-15 Uab Research Foundation Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
SE9903997D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
FR2814166B1 (fr) * 2000-09-21 2005-07-01 Innothera Lab Sa Derives 5-phenoxyindole et leurs applications therapeutiques
WO2002059110A1 (en) 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
DE60214990T2 (de) * 2001-01-30 2007-04-05 Eli Lilly And Co., Indianapolis Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
MXPA06007172A (es) 2003-12-23 2006-08-23 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-bencilamina como ssri.
WO2005111003A1 (en) * 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
CN102627607A (zh) * 2004-12-23 2012-08-08 艾尼纳制药公司 5HT2c受体调节剂组合物和使用方法
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
CN101258144B (zh) * 2005-08-12 2012-05-30 苏文生命科学有限公司 作为功能性5-ht6配体的氨基芳基磺酰胺衍生物
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
KR101415426B1 (ko) * 2005-09-27 2014-07-04 아이알엠 엘엘씨 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
CA2628260A1 (en) * 2005-11-09 2007-05-18 Abbott Laboratories 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof
TW200808780A (en) 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
BRPI0820632A2 (pt) 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
NZ596137A (en) 2009-05-14 2013-08-30 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN102491935B (zh) * 2011-11-28 2013-10-16 山东大学 硝基苯甲醛吲哚席夫碱及其制备方法和应用
CN102584671B (zh) * 2012-01-15 2013-08-07 山东轻工业学院 一种吲哚-3-甲醛缩联苯二胺双席夫碱及其制备方法
CN102584670B (zh) * 2012-01-15 2014-04-02 齐鲁工业大学 一种吲哚-3-甲醛缩苯二胺双席夫碱及其制备方法
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
MD3483164T2 (ro) 2017-03-20 2020-07-31 Forma Therapeutics Inc Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
NZ238424A (en) * 1990-06-07 1993-12-23 Wellcome Found 3,5-substituted indole derivatives; medicaments and preparatory processes.
HUT64326A (en) * 1990-10-15 1993-12-28 Pfizer Process for production indole derivatives and pharmaceutical preparations containing these compounds
DE9112614U1 (de) * 1991-10-10 1992-01-16 Fleddermann, Jörg, 8000 München Kindersitz für Fahrzeuge mit Airbag
KR0184911B1 (ko) * 1991-11-25 1999-05-01 알렌 제이. 스피겔 인돌유도체
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
ATE190608T1 (de) 2000-04-15
IL103798A0 (en) 1993-04-04
NZ245243A (en) 1995-12-21
TW229205B (es) 1994-09-01
UA41297C2 (uk) 2001-09-17
RU2126399C1 (ru) 1999-02-20
HUT69705A (en) 1995-09-28
DK0619805T3 (da) 2000-06-05
CN1045294C (zh) 1999-09-29
PT101087A (pt) 1994-06-30
JPH08239363A (ja) 1996-09-17
RU94028107A (ru) 1996-04-10
KR0184911B1 (ko) 1999-05-01
DE69230803D1 (de) 2000-04-20
PT101087B (pt) 1999-10-29
EP0619805B1 (en) 2000-03-15
MY109954A (en) 1997-10-31
BR9206810A (pt) 1995-10-31
FI942395A (fi) 1994-05-24
CZ281874B6 (cs) 1997-03-12
NO941918L (no) 1994-05-24
CZ128094A3 (en) 1995-02-15
WO1993011106A1 (en) 1993-06-10
CN1072679A (zh) 1993-06-02
ES2143992T3 (es) 2000-06-01
GR3033370T3 (en) 2000-09-29
CA2124206A1 (en) 1993-06-10
NO941918D0 (no) 1994-05-24
AU2896192A (en) 1993-06-28
IL103798A (en) 2000-08-13
JPH06510793A (ja) 1994-12-01
FI942395A0 (fi) 1994-05-24
NO301225B1 (no) 1997-09-29
DE69230803T2 (de) 2000-12-07
HU9401398D0 (en) 1994-08-29
AU671959B2 (en) 1996-09-19
NZ272130A (en) 1997-06-24
YU48456B (sh) 1998-08-14
PL173875B1 (pl) 1998-05-29
YU100892A (sh) 1995-10-03
ZA929082B (en) 1994-05-24
CA2124206C (en) 2001-02-27
EG21209A (en) 2001-01-31
US5639752A (en) 1997-06-17
JP2840448B2 (ja) 1998-12-24
EP0619805A1 (en) 1994-10-19

Similar Documents

Publication Publication Date Title
MX9206762A (es) Derivados de indol
MX9700693A (es) Derivados del 4-indol.
NO943261D0 (no) Indolderivater som 5-HT, agonister
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister